12th Congress of the European Hematology ... - Haematologica

12 th Congress of the European Hematology Association
65%) of patients with a major thrombotic event had a mutated JAK2
gene, in comparison to patients without thrombosis (12 of 45; 27%;
p=0.005). All of the JAK2 mutations were heterozygous in this series (1
IMF patient only acquired homozygosicity during follow-up). Of the
13 patients with JAK2 mutation in whom thrombosis occurred, only 3
had inherited thrombophilia (F.V Leiden-1, heterozygous protein C deficiency-1,
combination of the two-1) in parallel. Interestingly, the vast
majority of the patients with thrombosis (19 out of 21; 90%) had either
additional thrombophilia or JAK2 mutation. In contrast, in patients not
experiencing thrombosis, either additional thrombophilia or JAK2 gene
mutation was demonstrated only in 18 out of 45 (40%; p=0.0001). Conclusions.
Thrombosis in MPD-T may result from coincidence of major
risk factors: elevated platelet counts, an additional thrombophilic state
(mostly inherited thrombophilia) or JAK2 gene V617F mutation, the latter
yielding increased adhesiveness to leukocytes and platelets. Larger
scale prospective studies of these risk factors are warranted.
Supported by the Czech Ministry of Health Research project 00237360001.
1045
EXPLORING THE ROLE OF HEPCIDIN IN ERYTHROPOIESIS OF PATIENTS WITH MULTIPLE
MYELOMA
C. Kartsios, C. Kartsios, P. Kazila, M. Ditsa, E. Katodritou,
M. Koltsida, D. Mihou, V. Gastari, A. Skirta, D. Markala, K. Zervas
„Theagenion„ Cancer Hospital, THESSALONIKI, Greece
Background. Anemia is a frequent clinical manifestation in patients
with multiple myeloma (MM). Although its origin is multifactorial, an
imbalance of inflammatory cytokines (IL-1, TNF, IL-6), resulting in anemia
of chronic disease (ACD), appears to be its main cause. Recently, it
has been demonstrated that hepcidin, a peptidic hormone produced in
the liver under the stimulus of IL-6, has a key role in ACD by inhibiting
iron supply to the erythron. Aims. To explore if prohepcidin levels have
any impact on iron metabolism and erythropoiesis in untreated MM
patients. Patients and Methods. Blood samples from 31 MM patients [M/F:
13/18, median age: 66(40-83) years] and 16 healthy volunteers [M/F:
7/9, median age: 60(56-75) years] were analyzed. Hemoglobin, serum
pro-hepcidin (pro-HPC), erythropoietin (EPO) and interleukin-6 (IL-6)
levels, CRP, iron, ferritin, total iron binding capacity (TIBC), transferrin,
transferrin saturation and soluble transferrin receptors (sTFRs) were
measured in both groups. β-2 microglobulin and tumor necrosis factor-
A (TNF-A) levels were studied in the patients’ group, only. None of the
patients had smouldering myeloma, infection or second malignancy.
Mann Whitney U test, independent samples T test and Spearman’s rho
test were used for statistical analysis. Results. Compared to healthy volunteers,
MM patients had lower Hb (median: 10.6 g/dL vs 14.75 g/dL,
p